Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
112.54
-0.43 (-0.38%)
At close: Sep 15, 2025, 4:00 PM EDT
112.78
+0.24 (0.21%)
After-hours: Sep 15, 2025, 7:44 PM EDT
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.08B in the quarter ending June 30, 2025, with 1.84% growth. This brings the company's revenue in the last twelve months to $28.86B, up 3.81% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.86B
Revenue Growth
+3.81%
P/S Ratio
4.86
Revenue / Employee
$1,639,943
Employees
17,600
Market Cap
139.64B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
GILD News
- 5 days ago - Gilead Sciences, Inc. (GILD) Presents At Baird Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 days ago - Gilead Sciences, Inc. (GILD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 11 days ago - Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries - Business Wire
- 11 days ago - US plans to bring Gilead HIV drug to market in high-burden HIV countries - Reuters
- 11 days ago - Gilead Sciences, Inc. (GILD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Business Wire
- 12 days ago - Gilead Sciences, Inc. (GILD) Presents At Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 12 days ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters